Oakio Launches Tailored WPC Decking Solutions for European Outdoor Living
Oakio, a leading brand in WPC Decking, recently launched tailored solutions that elevate the quality of outdoor living. Enhancing outdoor living spaces has become a significant trend in Europe, driven by a desire for functional and aesthetic areas that reflect individual styles and needs.
Oakio WPC Decking: Tailored for Your Needs
Oakio WPC Decking excels in providing customized solutions that cater to diverse homeowner needs. With its slip-resistant and waterproof surface, Oakio decking ensures comfort and safety, making it ideal for families with children and elderly members. The decking is available in a variety of colours and finishes, allowing homeowners to select styles that perfectly match their outdoor aesthetic. Furthermore, Oakio’s decking mimics the natural look of wood while requiring minimal maintenance, providing both beauty and practicality.
Durability and Low Maintenance
Oakio WPC Decking stands out for its durability and low maintenance. Unlike traditional wood decking, it does not require regular staining or sealing, saving homeowners time and effort. The material is resistant to the effects of weather, pests, and rot, ensuring that it remains in excellent condition for years, even in Europe’s diverse climates.
Tailored Yard Transformations
Several homeowners have successfully transformed their yards using Oakio WPC Decking. For instance, a small urban backyard was upgraded into a cozy retreat, maximizing limited space with stylish and practical decking. In the suburbs, a large backyard was turned into a multifunctional outdoor living area, perfect for family gatherings and entertainment.
Expert and Customer Testimonials
Experts in landscape architecture praise Oakio’s design flexibility and quality. “Oakio WPC Decking offers an unparalleled combination of durability and aesthetic appeal,” says one landscape architect. Homeowners share glowing testimonials, highlighting enhanced outdoor living quality and overall satisfaction with the product. “Our new deck has completely transformed our backyard. It's beautiful, safe for our kids, and requires very little maintenance,” one satisfied customer shares.
Ideal Outdoor Decking Solution
Oakio WPC Decking offers a perfect combination of comfort, aesthetics, and durability, making it an excellent choice for anyone looking to upgrade their outdoor space. Its ability to provide tailored solutions that meet individual needs makes it a standout product in the market.
To learn more about Oakio WPC Decking and how it can transform your yard, visit www.oakio.com. Embrace the trend of enhancing outdoor living spaces with tailored solutions that reflect your unique style and needs.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240605007785/en/
Contacts
Juno Zhong
info@oakio.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 20245.11.2024 15:05:00 CET | Press Release
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will share new data across a range of B-cell malignancies and assets, including best-in-class Bruton’s tyrosine kinase (BTK) inhibitor BRUKINSA® (zanubrutinib), at the 66th ASH Annual Meeting and Exposition in San Diego, December 7-10. BeiGene has 21 abstracts accepted at ASH 2024, with four selected for oral presentation. “In the five years since its initial approval, BRUKINSA has become a standard of care for patients facing many B-cell malignancies, and our data featured at ASH demonstrated how long-term follow-up of treatment with BRUKINSA elicited deep and durable responses, including in patients with chronic lymphocytic leukemia and Waldenström’s macroglobulinemia,” said Mehrdad Mobasher, M.D., M.P.H., Chief Medical Officer, Hematology at BeiGene. “BRUKINSA is just the starting point – pipeline data for our BTK degrader BGB-16673 and BCL2 inhibitor sonrotoclax showcase our contin
DirectSens’ Market-Leading LactoSens ® Biosensor Technology Acquired by Kerry Group P.L.C.5.11.2024 14:00:00 CET | Press Release
DirectSens, a pioneer in next generation biosensor technology, announces the acquisition of its LactoSens® technology by Kerry Group, a global leader in taste and nutrition. The acquisition of LactoSens® reflects DirectSens’ success in developing end-to-end biosensor solutions and represents a move by Kerry Group to complement its offering in lactase enzymes. As an indispensable analytical tool, LactoSens® will work alongside Kerry Group’s ingredient solutions, enabling a more integrated offering for food manufacturers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241105399369/en/ LactoSens®, Industry Gold Standard Biosensor Kit. Developed and manufactured by DirectSens in Vienna, AUSTRIA, © DirectSens GmbH 2024 “We’re excited to bring LactoSens® into Kerry Group’s portfolio to add a new element to our offering, as we fully integrate LactoSens® into our broader solutions for the food and beverage industry.” — Ronan Moloney
Technology Holdings Has Expanded Operations into Brazil, Driving Growth in Latin America5.11.2024 13:35:00 CET | Press Release
Technology Holdings (TH), an award-winning global boutique investment bank with a track record of closing transactions in 24 countries, proudly announces its strategic expansion into Brazil, leveraging digital transformation within one of Latin America’s largest economies. This move significantly strengthens Technology Holdings’ presence in the rapidly growing Latin American market, enabling the firm to play a vital role in the region's expanding M&A landscape. According to Dealogic, M&A deals totaling $35 billion have been announced, reflecting a 56% increase compared to the same period last year. As companies increasingly look to consolidate and expand, Technology Holdings is uniquely positioned to provide strategic guidance and facilitate successful transactions. “The expansion into Brazil represents an exciting opportunity for us to deepen our relationships within this vibrant market,” said Edoardo Freschet, Head of Latin America at Technology Holdings. “The quality of talent and t
EUMETSAT: Lisbon Event Offers a Deep Dive Into Ocean Data5.11.2024 13:07:00 CET | Press Release
People with an interest in our oceans – from academics to businesspeople through to representatives from navies and weather services – are meeting in Lisbon, Portugal, for a deep dive into satellite data and its uses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241105106009/en/ (Photo: Business Wire) Europe’s meteorological satellite agency, EUMETSAT, the European Commission, the European Space Agency, the European Centre for Medium-Range Weather Forecasts and Mercator Ocean International are hosting the two-day event starting today. The aim is to showcase how data from the Copernicus Sentinel satellites are used to benefit agencies and businesses with an interest in the marine environment, to connect data users with different skills and expertise, and to receive feedback on how to better meet the needs of existing and potential data users. “What happens in our oceans influences everyone’s lives by impacting our weather,
Delta-Fly Pharma Inc.: Update for Expanded Phase I Study of DFP-149275.11.2024 12:00:00 CET | Press Release
We are excited to share our latest development status. As informed dated October 28th, an interim analysis for the Phase III study ofDFP-10917 in R/R AML patients is ongoing. The Phase I/II combination study of DFP-10917 with Venetoclax in AML patients is well ongoing. Today, we are delighted to talk about an update for development of the drug delivery of DFP-10917 selective to solid tumor, which is namely, DFP-14927 showed nice safety and efficacy in the Phase I study in solid tumor patients. Accordingly, we have moved forward into an expanded Phase I study of DFP-14927 at 3200 mg/m2 weekly dosing in R/R colorectal cancer patients at MD Anderson Cancer Center and UCLA. Efficacy in expanded Phase I study is evaluated by Disease Control Ratio (DCR) and it shall be evaluated by OS in the next registration study for NDA approval. View source version on businesswire.com: https://www.businesswire.com/news/home/20241105884234/en/
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom